<DOC>
	<DOC>NCT01403818</DOC>
	<brief_summary>This study is to assess the pharmacokinetic interaction between ASP1941 and Mitiglinide calcium hydrate in healthy volunteers.</brief_summary>
	<brief_title>A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration</brief_title>
	<detailed_description>This will be a randomized, open label, four group, two-way crossover design study to assess the effect of drug interaction between ASP1941 and Mitiglinide calcium hydrate on the pharmacokinetics of them after separate and concomitant administration to healthy non-elderly adult male subjects.</detailed_description>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<criteria>Healthy as judged by the investigator/subinvestigator based on the results of physical examinations and laboratory tests Body weight ; ≥50.0 kg, &lt;80.0 kg Body Mass Index ; ≥17.6, &lt;26.4 kg/m2 Written informed consent has been obtained Received any investigational drugs within 120 days before the screening assessment Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or d components within 14 days before the screening assessment Received medication within 7 days before hospital admission A deviation from the assessment criteria of physical examinations or laboratory tests at screening or upon admission History of drug allergies With renal, hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases Previous treatment with ASP1941</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>ipragliflozin</keyword>
	<keyword>Mitiglinide calcium hydrate</keyword>
	<keyword>Drug-Drug interaction</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>